Gynecologic cancer: Edited by Anne O. RodriguezUse of combined radiation and hyperthermia for gynecological cancerFranckena, Martine; van der Zee, JacobaAuthor Information Erasmus Medical Center, Daniel den Hoed Cancer Center, Department of Radiation Oncology, Rotterdam, The Netherlands Correspondence to Martine Franckena, Erasmus Medical Center, Daniel den Hoed Cancer Center, Department of Radiation Oncology, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands Tel: +31 10 7041470; fax: +31 10 7041022; e-mail: firstname.lastname@example.org Current Opinion in Obstetrics and Gynecology: February 2010 - Volume 22 - Issue 1 - p 9-14 doi: 10.1097/GCO.0b013e328333d1e2 Buy Metrics Abstract Purpose of review We reviewed all literature on the clinical use of combined radiation and hyperthermia for gynecologic malignancies. Recent findings Combined radiation and hyperthermia should be considered an alternative to chemoradiation for patients with locally advanced cervix cancer and be the first treatment of choice for these patients when radiation cannot be combined with chemotherapy. Several randomized trials have shown an improvement by adding hyperthermia to radiation that is comparable to the improvement found with the addition of chemotherapy to radiation. Hyperthermia does not seem to add to treatment-induced toxicity and the results of hyperthermia are consistent even at 12 years follow-up and could be reproduced in a large, unselected group of cervix cancer patients. A novel indication for combined radiotherapy and hyperthermia is vaginal cancer. Recently, a cohort study showed that the addition of hyperthermia to radiation seems to improve overall survival for patients with vaginal cancer International Federation of Gynecology and Obstetrics stage III. Summary Combined radiation and hyperthermia should be considered for patients with locally advanced cervix cancer (International Federation of Gynecology and Obstetrics stage IIb and upwards) as an alternative to chemoradiation for patients with a contraindication for chemotherapy. For other patients, the optimal treatment combination is the subject of randomized trials. For vaginal cancer, a prospective registration study is currently ongoing. © 2010 Lippincott Williams & Wilkins, Inc.